One-third of patients skip DOACs within six months

As many as one in three patients stop taking their direct-acting oral anticoagulants (DOACs) soon after being prescribed them, researchers have found.

In findings that suggest the real-world impact of DOACs may be less than seen in clinical trials, a Canadian study of 26,000 patients treated with the drugs found that 36% of dabigatran users and 32% of rivaroxaban users stopped taking the medications for at least two weeks within six